Pirfenidone, an antifibrotic and anti-inflammatory agent capable of inhibiting fibroblast proliferation and collagen deposition by targeting the TGF-β pathway, has gained approval for the treatment of IPF with a recommended full oral dosage of 2403 mg/day divided into three doses [8]. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.